Drug intelligence / Profile preview

GI-6100

Development stage: Unknown
Lead developer: GlobeImmune
Modality: Vaccines & Immunotherapeutics

Overview

**GI-6100** is a preclinical immunotherapy drug initially developed by GlobeImmune, Inc., designed as a MUC1 modulator targeting the Mucin-1 (MUC1) protein, which is overexpressed in various cancers. It belongs to GlobeImmune's Tarmogen platform of yeast-based vaccines intended to stimulate immune responses against tumor-associated antigens like MUC1 for potential use in oncology indications. Rights to the program were licensed to NantCell (a subsidiary of ImmunityBio/NantWorks) for further development, potentially in combination with other agents in cancers expressing relevant targets.[1][3][12]

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on GI-6100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GI-6100.

Explore the full profile